On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

On location

Post-Transplant Ixazomib Maintenance Prolongs Survival in Newly Diagnosed Myeloma

For patients with newly diagnosed multiple myeloma (MM) who relapse following autologous hematopoietic cell transplantation (AHCT), maintenance therapy with the oral proteasome inhibitor (PI)...
On location

Adoptive “Non-Engineered” T-Cell Therapy Shows Preliminary Efficacy in Lymphomas

Chimeric antigen receptor (CAR) T-cell therapies engineered to recognize and destroy CD19 antigens on the surface of lymphoma cells have revolutionized the treatment of...
On location

Beta-Thalassemia Gene Therapy Continues to Show Efficacy in Longer-Term Follow-up

Updated results from the phase I/II HGB-204 and HGB-207 trials indicated that several patients with severe, transfusion-dependent beta-thalassemia have remained transfusion-free up to four...
On location

Prognostic Significance of Post-Transplant MRD Varies Based on Conditioning Regimen in ALL

Assessment of measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplantation (alloHCT) is an established important prognostic factor in patients with acute lymphocytic...
On location

A Safer Conditioning Regimen for Patients With Bone Marrow Failure and Short Telomeres?

A study of patients with bone marrow failure (BMF) and short telomeres found that a conditioning regimen that eliminates radiation and DNA-alkylating agents led...
On location

Alemtuzumab Plus Myeloablative Conditioning Reduces Post-Transplant GVHD Risk

For younger patients with sickle cell disease (SCD) who are eligible for a hematopoietic cell transplantation (HCT), adding alemtuzumab lowered the risk of graft-versus-host...
On location

Salvage Transplant Versus Continuous Therapy: Insights From the Myeloma ReLApsE Trial

For patients with multiple myeloma (MM) that has relapsed following autologous hematopoietic cell transplantation (AHCT), a standard salvage therapy approach involves high-dose chemotherapy and...
On location

Venetoclax Plus R-CHOP Improves Outcomes in BCL2-Positive DLBCL

For the substantial portion of patients with diffuse large B-cell lymphoma (DLBCL) with overexpression of the BCL2 protein, combining the BCL2 inhibitor venetoclax with...
On location

Rituximab-Lenalidomide Combo Superior to Rituximab Alone in Relapsed/Refractory Indolent NHL

For patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL), adding lenalidomide to rituximab treatment improved response rates and prolonged time to next treatment, compared with...
On location

Evaluating Ixazomib Regimens in Patients With Newly Diagnosed Myeloma

Two studies presented at the 2018 ASH Annual Meeting explored the use the oral proteasome inhibitor (PI) ixazomib in patients with newly diagnosed multiple...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.